THE EFFECT OF DAPAGLIFLOZIN ON THYROID FUNCTION TEST IN DIABETIC PATIENTS

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type II Diabetes Mellitus (T2DM) is characterized by hyperglycemia due to insulin resistance and reduced insulin secretion.
• Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, enhances urinary glucose excretion to lower blood glucose levels.
• SGLT2 inhibitors may exert additional systemic effects beyond glucose regulation.

Purpose of the Study:

• To evaluate the impact of dapagliflozin on glycemic control (HbA1c).
• To assess changes in thyroid function (T3, T4, TSH) and serum vitamin D3 levels.
• To investigate potential influences of patient age and gender on these effects.

Main Methods:

• A cohort of 30 T2DM patients (18 male, 12 female, ages 31-70) previously on metformin was enrolled.
• Participants received 10 mg of dapagliflozin daily for eight weeks, in addition to metformin.
• Serum levels of HbA1c, T3, T4, TSH, and vitamin D3 were measured pre- and post-treatment using chemiluminescent and ELISA assays.

Main Results:

• Dapagliflozin significantly reduced HbA1c and T3 levels.
• No statistically significant changes were observed in T4, TSH, or vitamin D3 levels.
• Neither age nor gender demonstrated a significant impact on the measured biochemical parameters, although trends for HbA1c and vitamin D3 approached borderline significance.

Conclusions:

• Dapagliflozin primarily influences peripheral metabolic regulation, effectively improving glycemic control without significant alterations to thyroid hormones or vitamin D3.
• The drug exhibits a consistent therapeutic profile across diverse demographic groups (age, gender).
• Further research with larger cohorts and extended follow-up is warranted to fully elucidate dapagliflozin's long-term effects and mechanisms.